SI CONSIDERANO AD ALTO RISCHIO:
Acute leukemia during active therapy (both induction and consolidation) mainly to prevent HSV reactivation
Autologous Stem Cell Transplant mainly to prevent HSV reactivation
Therapy with proteasome inhibitors, mainly to prevent VZV reactivation
Therapy with alemtuzumab, to prevent both HSV and VZV reactivation
Lymphoprolipherative diseases requiring intensive and/or immunosuppressive treatment and with low CD4 count (<200/cmm) to prevent both HSV and VZV reactivation.
Patients with recurrent HSV or VZV reactivation.